User profiles for Imre Pavo
 | Imre PavoClinical Research Physician, Eli Lilly, Vienna Verified email at lilly.com Cited by 5530 |
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 …
Background We aimed to assess efficacy and safety, with a special focus on cardiovascular
safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine …
safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine …
[HTML][HTML] Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under
development for the treatment of type 2 diabetes (T2D) and obesity. Its association with …
development for the treatment of type 2 diabetes (T2D) and obesity. Its association with …
Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
…, SJ Martin, G Crans, I Pavo - Journal of bone and …, 2004 - academic.oup.com
We investigated the effects of 18 months of treatment with teriparatide in patients previously
treated with long‐term antiresorptive therapy using bone turnover markers and bone …
treated with long‐term antiresorptive therapy using bone turnover markers and bone …
Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data
…, N Nyolczas, N Pavo, J Bergler-Klein, IJ Pavo… - Circulation …, 2015 - Am Heart Assoc
Rationale: The meta-Analysis of Cell-based CaRdiac study is the first prospectively declared
collaborative multinational database, including individual data of patients with ischemic …
collaborative multinational database, including individual data of patients with ischemic …
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 …
Background In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …
Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes
I Pavo, G Jermendy, TT Varkonyi… - The Journal of …, 2003 - academic.oup.com
Pioglitazone, a thiazolidinedione, improves glycemic control primarily by increasing peripheral
insulin sensitivity in patients with type 2 diabetes, whereas metformin, a biguanide, exerts …
insulin sensitivity in patients with type 2 diabetes, whereas metformin, a biguanide, exerts …
Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy
…, LG Ste-Marie, JC Gallagher, I Pavo… - The Journal of …, 2005 - academic.oup.com
Context: Biochemical markers of bone turnover may reflect bone structure during anabolic
treatment. Objective: The objective was to evaluate associations between changes in …
treatment. Objective: The objective was to evaluate associations between changes in …
Serial noninvasive in vivo positron emission tomographic tracking of percutaneously intramyocardially injected autologous porcine mesenchymal stem cells modified …
…, IJ Pavo, I Kertész, L Balkay, N Pavo… - Circulation …, 2008 - Am Heart Assoc
Background— Porcine bone marrow-derived mesenchymal stem cells (MSCs) were stably
transfected with a lentiviral vector for transgene expression of the trifusion protein renilla …
transfected with a lentiviral vector for transgene expression of the trifusion protein renilla …
Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of …
Raloxifene reduces vertebral fracture risk in postmenopausal women with osteoporosis and
established osteoporosis, but its efficacy in women with osteopenia has not been studied. …
established osteoporosis, but its efficacy in women with osteopenia has not been studied. …
[HTML][HTML] Discovery of drug–omics associations in type 2 diabetes with generative deep-learning models
The application of multiple omics technologies in biomedical cohorts has the potential to reveal
patient-level disease characteristics and individualized response to treatment. However, …
patient-level disease characteristics and individualized response to treatment. However, …